Morgillo F - Search Results

1

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Cascone T, et al. Among authors: morgillo f. J Cell Physiol. 2008 Sep;216(3):698-707. doi: 10.1002/jcp.21444. J Cell Physiol. 2008. PMID: 18381602

2

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.

De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G. De Vita F, et al. Among authors: morgillo f. Cancer. 2004 Jan 15;100(2):270-8. doi: 10.1002/cncr.11911. Cancer. 2004. PMID: 14716760 Free article.

3

Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).

Orditura M, Quaglia F, Morgillo F, Martinelli E, Lieto E, De Rosa G, Comunale D, Diadema MR, Ciardiello F, Catalano G, De Vita F. Orditura M, et al. Among authors: morgillo f. Oncol Rep. 2004 Sep;12(3):549-56. Oncol Rep. 2004. PMID: 15289836 Review.

4

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Tuccillo C, et al. Among authors: morgillo f. Clin Cancer Res. 2005 Feb 1;11(3):1268-76. Clin Cancer Res. 2005. PMID: 15709198

5

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Han JY, et al. Among authors: morgillo f. J Natl Cancer Inst. 2005 Sep 7;97(17):1272-86. doi: 10.1093/jnci/dji251. J Natl Cancer Inst. 2005. PMID: 16145048

6

Resistance to epidermal growth factor receptor-targeted therapy.

Morgillo F, Lee HY. Morgillo F, et al. Drug Resist Updat. 2005 Oct;8(5):298-310. doi: 10.1016/j.drup.2005.08.004. Epub 2005 Sep 19. Drug Resist Updat. 2005. PMID: 16172017 Review.

7

Lonafarnib in cancer therapy.

Morgillo F, Lee HY. Morgillo F, et al. Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. doi: 10.1517/13543784.15.6.709. Expert Opin Investig Drugs. 2006. PMID: 16732721 Review.

8

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Morgillo F, et al. Cancer Res. 2006 Oct 15;66(20):10100-11. doi: 10.1158/0008-5472.CAN-06-1684. Cancer Res. 2006. PMID: 17047074

9

Combination of standard chemotherapy and targeted agents.

Bareschino MA, Morgillo F, Ciardiello F. Bareschino MA, et al. Among authors: morgillo f. J Thorac Oncol. 2007 May;2(5 Suppl):S19-23. doi: 10.1097/01.JTO.0000268636.02709.b4. J Thorac Oncol. 2007. PMID: 17457224 Free article. Review. No abstract available.

10

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Morgillo F, et al. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077. Clin Cancer Res. 2007. PMID: 17473213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters